Beth Israel Deaconess Medical Center: Message of Hope

April 4, 2008
A Message of Hope
Listen to Beth Israel Deaconess Medical Center's Message of Hope

A major teaching hospital of Harvard Medical School, Beth Israel Deaconess Medical Center was created in 1996 through the merger of two prominent institutions, Beth Israel Hospital and New England Deaconess Hospital. Renowned for excellence in patient care, teaching and community service, BIDMC is also home to a preeminent academic research program, widely recognized for its translational "bench to bedside" research.

BIDMC's 264 principal investigators, all of whom are Harvard Medical School faculty, lead more than 850 active sponsored projects and more than 500 funded and non-funded clinical trials. Today, research at BIDMC is a $200 million enterprise, consistently ranking in the top four in National Institutes of Health (NIH) funding among independent hospitals nationwide.

Studies by BIDMC researchers are routinely published in the world's leading scientific journals including Nature, Science and The New England Journal of Medicine. Vascular biology - the study of the structure and function of the body's blood vessels - is a key area of research at BIDMC, as are molecular imaging, transplantation, signal transduction, cancer biology, metabolic disease and obesity, neurobiology, AIDS, inflammation and cardiology/cardiac surgery.

Technology Ventures Office

Since its creation in 1998, BIDMC's Technology Ventures Office has helped to translate hundreds of scientific discoveries from the labs of BIDMC scientists into commercial ventures that improve human health. BIDMC revenue from new and existing TVO deals totaled more than $10 million in 2006.

TVO-initiated strategic alliances with global health care companies including Japan's Takeda Pharmaceuticals, Merck, AGA Linde, and GE Health Care provide BIDMC researchers with many years and millions of dollars of research support, and provide efficient avenues for the translation of important new discoveries into new drugs, diagnostics, and imaging agents for diabetes, obesity, cancer, and heart disease.
Recent patents to emerge from the TVO office include a new method for diagnosing and treating sepsis, a device for the treatment of congestive heart failure, and several new compounds that hold promise for the treatment of cancer, diabetes, colitis, cystic fibrosis, and numerous other diseases.
The TVO team's successful partnerships with industry have led to the development of new biomedical products that are helping patients worldwide. Some examples include of products that have been derived from inventions made at BIDMC: Zenapax (sold by Roche) and Simulect (sold by Novartis) drugs that help patients tolerate newly transplanted organs; Impact (sold by Novartis), Optimental (sold by Ross), and Immnuo-Aid (sold by McGraw), nutritional supplements that are used in chronic care and post-surgical settings; the Cohn Stabilizer, a medical device sold by Teleflex that assists surgeons in the performance of off-pump open-heart surgery; T-Wave Alternans, an algorithm recently approved by the FDA, sold by GE and Medtronic, that predicts sudden heart failure; and SMASH, a technique developed at BIDMC to improve the resolution of magnetic resonance imaging, (sold by Siemens, GE, and Bruker.)

In addition, the TVO office has catalyzed the formation of over 20 new biomedical startup companies, including DeCode Genetics, Elixir Pharmaceuticals, Synta Pharmaceuticals, Cequent, and Tolerance. Many of these companies are developing leading-edge technologies that could lead to be the next generation of new medicines.
Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Upcoming Events email!
For Email Marketing you can trust

MassBio